Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 52.5 EUR 2.34%
Market Cap: 927.2m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Investor Relations

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Show more

Earnings Calls

No Earnings Calls Available

Management

Dr. Stefan Glombitza
CEO & Member of Executive Board
No Bio Available
Dr. Nicolas Combe Ph.D.
Co-Founder
No Bio Available
Mr. Enno Spillner
CFO & Member of Management Board
No Bio Available
Dr. Andreas Seidl
Chief Scientific Officer & Member of Executive Board
No Bio Available
Ms. Nicola Mikulcik
Chief Business Officer & Member of Executive Board
No Bio Available
Sabrina Muller
Director of Investor Relations & Corporate Communications
No Bio Available

Contacts

Address
BAYERN
Martinsried
Fraunhoferstrasse 15
Contacts
+4989864667100.0
www.formycon.com